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Networks.
D. Napoletani ∗, M. Signore†, T. Sauer‡, L. Liotta §, E. Petricoin§
Abstract
In a previous paper we introduced a method called augmented sparse
reconstruction (ASR) that identifies links among nodes of ordinary differ-
ential equation networks, given a small set of observed trajectories with
various initial conditions. The main purpose of that technique was to
reconstruct intracellular protein signaling networks.
In this paper we show that a recursive augmented sparse reconstruc-
tion generates artificial networks that are homologous to a large, reference
network, in the sense that kinase inhibition of several reactions in the net-
work alters the trajectories of a sizable number of proteins in comparable
ways for reference and reconstructed networks. We show this result using
a large in-silico model of the epidermal growth factor receptor (EGF-R)
driven signaling cascade to generate the data used in the reconstruction
algorithm.
The most significant consequence of this observed homology is that a
nearly optimal combinatorial dosage of kinase inhibitors can be inferred,
for many nodes, from the reconstructed network, a result potentially useful
for a variety of applications in personalized medicine.
Keywords: sparse network reconstructions, protein network models,
signaling pathways, kinase inhibitors.
1 Introduction
One of the most intriguing and promising fields in medical research is based
on the assumption that the great amount of information generated by high
throughput technologies would allow us to understand cancer’s complexity at
various levels. In recent years, the completion of the Human Genome Project
and other rapid advances in genomics have led to increasing anticipation of an
era of genomic and personalized medicine, in which an individual’s health is
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optimized through the use of all available patient data, including data on the
individual’s genome and its downstream products.
Because variations in individuals’ genetic profiles oftentimes correlate with
differences in how individuals develop diseases and respond to treatment, per-
sonalized medicine supported by genetic and genomic assays has the poten-
tial to facilitate optimal risk identification, disease screening, disease diagnosis,
therapy, and monitoring [Kawamoto et al. 2009], [Willard and Ginsburg 2009],
[West et al. 2006]. In addition to genomic assays, proteomic and metabolomic
signatures hold great potential for serving as pillars of personalized medicine in
the future [Willard et al. 2005], [Beretta 2007], [Gerszten et al. 2008], [Lewis et al. 2008],
[Kaddurah-Daouk et al. 2008].
While personalized medicine guided by genomics is still in early stages of
development, individuals’ genetic profiles are already starting to be used to guide
patient care. As some examples, clinicians can obtain gene expression profiles of
breast cancer samples to guide management [Paik et al. 2006], genotypes of HIV
samples to identify the optimal antiretroviral regimen [Blum et al. 2005], and
genetic profiles of patients’ cytochrome P450 drug metabolizing system to guide
the selection and dosing of pharmacotherapies [de Leon et al. 2006]. However,
it is the proteins that form the actual cell signaling and metabolic networks
within the cell. Indeed, for the new classes of molecular targeted inhibitors,
it is the proteins that are the drug targets, not the genes, and the molecular
networks are underpinned by protein and protein phosphorylation.
Personalized medicine could be directed towards the generation of protein-
based molecular maps of cancer networks in order to target malignant cells in
their specific and unique context. The usefulness of patient-tailored therapy
comes from the potential ability to depict patient-specific molecular circuitries
and hence translate each targeted treatment in a favorable clinical response
[Petricoin et al. 2005].
On the other hand, we still lack the ability to dynamically measure and col-
lect enough data from every protein/node within networks with current method-
ologies. This restriction forces on us a shift in mind set, in the sense that, rather
than attempting a full reconstruction and understanding of cell pathways, we
should search for equivalent, indistinguishable, classes of models that project to
the same network structure, in the sense that such classes should ideally give
rise, for each protein/node, to trajectories that are qualitatively similar even
when the details of the topology of the connections among nodes differ.
The potential therapeutic implications of such an approach are evident if
we consider the great heterogeneity of cancer patients. Individuals with sim-
ilar stages of the disease show diverse therapeutic responses that are often-
times not predictable on the basis of genetic mutation analysis. Primary cancer
stem cells (CSCs) from a variety of tumors have been isolated and charac-
terized and clear evidences exist of their association with tumor’s resistance
to chemo- and radio-therapy, making CSCs a useful and effective target for
cancer research ([Ailles and Weissman 2007], [Gilbert and Ross 2009]). More-
over, an extensive proteomic, genetic and drug sensitivity profiling of the NCI60
cell line set has recently highlighted the importance of direct studies on can-
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cer cells in order to associate drug responsiveness to specific molecular sig-
natures ([Park et al. 2010]). Such studies, and clinical experience, call for a
multi-targeted approach to cancer treatment and underscore the importance of
molecular biomarkers ([Zahorowska et al. 2009]). Therefore, an in-silico system
capable of reconstructing the behavior of deregulated cancer cell signaling net-
works holds a significant experimental value in the prediction of therapeutic
responses based on individual patients molecular characteristics.
Our approach to the problem of controlling protein signaling networks starts
with this broad methodological assumption, but it necessarily moves further
than that, since it is not yet clear what we should consider as a measure of
similarity of trajectories for general, large networks. It is likely that properties
such as the shape of the trajectories, the location of their maxima, as well as
the value of the maxima themselves, are among the critical factors in deciding
whether or not a given signaling response is triggered.
For example, activation of EGF-R, which is an upstream node and it is
governed only by the kinetics and thermodynamics of EGF/EGF-receptor in-
teraction and the biochemistry of the kinase domain, is expected to be similar
across cell lines. In contrast, signals further down the cascade are modulated
by many upstream proteins, many of whose concentrations and rate constants
impact on the overall output.
Despite this complex network behavior, there is a strong correlation between
specific cell functions and the maximum concentration of key proteins known
to be involved in cell growth, proliferation, survival and death, suggesting that
suppression/enhancement of the activity of specific nodes can be seen potentially
as a way to achieve the final goal of disruptively interfering with the functioning
of cancer cells.
The trajectories for each node are usually generated in vitro by stimulation
of cell lines and subsequent relaxation to steady state, so that the extent of
suppression of a node activity can be determined by looking at the maximum
value of a relatively simple curve.
Even though the maximum activity of nodes is only one of many key features
of signaling networks, its accurate modification is by no means an easy task.
Agents directed at an individual target in the network frequently show limited
efficacy, poor safety and resistance profiles, which are often due to factors such
as network robustness, redundancy, crosstalk, compensatory and neutralizing
actions and anti-target and counter-target activities.
The ability to predict in silico the sensitivity of cancer cells to the inhibi-
tion of multiple reactions would allow us to combine drugs in order to achieve
synergy and/or potentiation of several orders of magnitude, while avoiding un-
desired effects on normal cells. Systems-oriented approaches has already yielded
several clinical successes and drug-discovery efforts are now focused towards near
optimal combinatorial treatments that target cell pathways at several sites.
Because the fundamental goal of a combinatorial approach to cancer therapy
is the control of the activity of specific nodes in the network, we use it to define
an operative notion of homologous networks. We select a target node N , and a
set of reactions P , and we assume the following definition of homology of net-
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works: two networks are homologous (with respect to N and P ) if the activity
of node N reacts in a similar way to the suppression of the given reactions P
performed by known kinases.
Note that this comparison can be made on very long time scales, ideally on
time intervals where the networks have each relaxed to the steady state, so that
the comparison of the networks can be considered global.
Remark 1: In Section 3 we define more formally similarity as the concor-
dance of the relative magnitude of the maximum difference of the trajectories of
the node N , starting from equal initial conditions, when control of the reactions
in the networks, via kinase inhibition, is on, and when control is off. In this
way, we have a simple, even though partial, way to determine how close two
networks will react, for specific nodes, to similar control schemes.
In a previous paper [Napoletani et al. 2008] we introduced a method called
augmented sparse reconstruction (ASR) that identifies links among nodes of
ordinary differential equation (ODE) networks, given a small set of observed
trajectories with various initial conditions. The main purpose of that technique
was to reconstruct intracellular protein signaling networks under the assumption
that most nodes interact with only a small fraction of the total number of
nodes in the network. We say in that case that the network is sparse and such
information can greatly help in reconstructing the network itself.
In this paper we show that augmented sparse reconstruction generates ar-
tificial networks that are homologous to the initial network, in the sense that
kinase inhibition of several reactions in the network alters the trajectories of a
sizable number of proteins in comparable ways. We show this surprising result
using an in silico model of the epidermal growth factor receptor (EGF-R) driven
signaling cascade to generate the initial observed trajectories.
The most significant consequence of this observed homology is that the the
optimal combinatorial dosage of kinase inhibitors can be inferred in many cases
from the reconstructed network1. This result could be of great value for a variety
of applications in personalized medicine.
While there have been successful attempts to derive network models from
a limited number of perturbation experiments (see for example the recent works
[Nelander et al. 2008], [Munsky et al. 2009]), we stress that our method achieves
a degree of reconstruction and dynamical control for nodes of a network whose
size far exceeds those tested so far in the literature, with the exception of the
very interesting work in [Chang et al. 2009], which uses sparsity in an essen-
tial way, but that builds only a static model rather than a dynamical one. A
significant amount of information can be inferred by static analysis, however
a full network control in non-stationary conditions can only be achieved in a
dynamical setting.
In section 2 we will show how the algorithm we described in [Napoletani et al. 2008]
needs to be modified to take into consideration knowledge of specific reactions
that can be inhibited. Sections 3 and 4 are dedicated to comparison between an
1A patent application has been filed for the methods described in this paper. Patent
application number 12/959,096, filed on 12/02/2010
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initial network and partially homologous networks obtained from its trajectories
by augmented sparse reconstruction.
2 Matching Pursuit for Augmented Sparse Re-
construction
Because of our very limited understanding of the changes of dynamics in large,
perturbed networks (except in those cases when the parameters of the model
of individual nodes are only slightly perturbed), it is daunting to set up an
homologous network from first principles, given a reference network.
We believe that the right approach to generate homologous networks is to
directly use the state space, in the sense that by modifying or restricting infor-
mation on the trajectories, we can use reconstruction methods to give candidate
homologous networks of a reference network. Effectively, this is a signal pro-
cessing approach to network dynamics: optimal signal representation of the
trajectories becomes the main tool to explore network structure.
We select a well established model of the epidermal growth factor receptor
(EGF-R) signaling pathway as reference network [Schoeberl et al. 2002]. The
reason of such choice is the great importance of the epidermal growth factor
receptor signaling pathway in cancer biology and the fact that it is one of the
most well-studied pathways that regulate growth, survival, proliferation, and
differentiation in mammalian cells [Oda et al. 2005].
In the EGF-R network, upon binding of the ligand, the receptors dimerize
and phosphorylate each other, thus generating docking sites for five adaptor
proteins and five enzymes. Signals from ErbBs converge to molecules forming
a bow-tie core and are supposed to represent a versatile and conserved group
of molecules and interactions. The amplitude of EGF-R cascades reaches high
levels within minutes of stimulus and an important role is played by the recy-
cling mechanism of receptor molecules after signal transduction, so that, in the
absence of EGF molecules the system relaxes back to steady state, in line with
the generic description of trajectories put forward in Section 1. The four human
ErbB receptors induce a wide variety of cellular responses thereby generating a
complex protein interaction network [Jones et al. 2006].
Due to its properties and involvement in tumor progression, the EGF-R net-
work inspired several experimental and mathematical modeling studies [Birtwistle et al. 2007],
[Uetz and Stagljar 2006]. Deregulation of EGF-R signaling plays a key role in
numerous cancers, including glioblastomas, breast cancer, and non−small cell
lung cancer (NSCLC) [Kumar et al. 2008].
Another reason to choose the EGF-R pathway as a reference network is
that, despite the fact that various agents have been developed to target EGF-
R, there is a need for improved strategies to integrate anti-EGF-R agents with
conventional therapies and to explore combinations with other molecular targets
[Baselga and Arteaga 2005].
In this work we use the differential equation model of EGF-R network put
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forward in [Schoeberl et al. 2002]and [Hornberg et al. 2005]. This model as-
sumes only linear and quadratic terms in the representation of the derivative
of the activity of each node of the network. Linear terms correspond to uni-
molecular interactions and quadratic terms correspond to bimolecular interac-
tions.
From the computational point of view, an important feature of this network
is its large size (103 variables and 148 distinct reactions). Most reconstruction
techniques are not able to deal with the reconstruction and control of very large
networks, if the experimental data are limited and noisy, and yet this is exactly
the size of networks that are of interest when exploring pathways that may not
be well understood.
In equation (1) we show the model of the network at a node n, in the specific
integral form that is used in augmented sparse reconstruction; for a complete
analysis of this integral model we refer to [Napoletani et al. 2008]. Essentially,
equation (1) is nothing else than the integral of a differential equation with
linear and quadratic terms, and with added random terms to make sure the
reconstruction algorithm is able to eliminate errors-in-variables due especially
to the presence of non-linear terms.
xn(t)− xn(t0) = a0n +
N∑
i=1
lin
∫ t
t0
xidt+ βq
N∑
i=1
N∑
j=1
qijn
∫ t
t0
xixjdt (1)
+
G∑
g=1
wgnng.
Here the βq ≤ 1 represent positive attenuation coefficients for the quadratic
terms. The systems parameters at node n that we need to determine are: a0n,
lin, i = 1, ..., N , qijn, i, j = 1, ..., N . The ng, g = 1, .., G are discrete random
vectors normally distributed, scaled to have norm 1 and multiplied by suitable
parameters wgn to be determined together with the system parameters.
The reconstruction algorithm of [Napoletani et al. 2008] assumes sparsity of
the network, i.e. we assume that each node interacts with only a small number
of nodes compared with the total of possible nodes. This assumption implies
that the number of terms in each equation in (1) with nonzero parameters is
small compared to the total possible number of terms.
Sparsity plays a crucial role in our method, since it allows to use fast linear
programming techniques in looking for the optimal model that has as few terms
as possible [Chen et al. 1998], but just as important for network reconstruction
is the fact that our method avoids a direct estimate of the derivative of the
trajectories, and that we augment the model with random terms. Despite these
adjustments, the quality of the reconstruction worsen for nodes with many links,
even when the total number of nonzero terms in equation (1) is low compared
to the total number of possible terms.
Though sparsity methods are very powerful, when properly adapted to net-
works, and they allow for significant inference of the network under limited and
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noisy data, it is unlikely that they, or any other currently known methods, will
fully reconstruct the network structure from very limited, coarse data.
Despite these limitations, the fundamental claim of this work is that we can
have homologous control despite our inability to gain full reconstruction of the
topology of a network. This claim is intrinsically related, in ways that still need
to be explored, to a fundamental assumption of systems biology, i.e. the belief
that biological networks are robust under variations of the strength and type of
connections of the signaling pathways.
Robustness seems to be a consequence of several recurrent factors, for exam-
ple the bow-tie architecture (or hourglass structure) of the EGF-R network is
considered a characteristic feature for robust evolvable systems [Kitano 2004].
Another important feature of robust biological networks is the fact that they
show a diverse array of molecules for input and output, that are connected to the
conserved core of the network with highly redundant and extensively crosstalk-
ing pathways and feedback control loops in various places in the pathway.
If the assumption of robustness is correct for most biological networks, aug-
mented sparse reconstruction may not recover the exact network, but it may be
sufficiently accurate to infer a network that is homologous to the original one.
We will see that this possibility is realized for our EGF-R reference model.
In this work we assume that specific reactions must be present in the recon-
struction of the network, since we define homologous systems with respect to
the action of kinase inhibitors. In [Napoletani et al. 2008] there was no such
constraint, therefore our main objective in this section is to adapt the algorithm
developed in that work in such a way that it guarantees the presence of specific
reactions to be targeted with available kinase inhibitors.
Signal processing sparsity methods, that are at the core of augmented sparse
reconstruction, are not able to guarantee the presence of these individual reac-
tions, since they are more concerned with global optimality of the representation
of each node. We need therefore an adaptive, recursive augmented reconstruc-
tion algorithm to extract the few terms in each equation due to the chosen
reactions, before we apply the augmented sparse reconstruction algorithm to
the whole representation system.
To understand the details of the reconstruction algorithm, we first recall
how individual reactions are put together in a modular way to generate sys-
tems of differential equations describing the network of [Schoeberl et al. 2002],
[Hornberg et al. 2005].
Suppose that phosphorylated proteins xi and xj are interacting to phospho-
rylate protein xk, and in the process they get de-phosphorylated; this specific
reaction can be modelled [Schoeberl et al. 2002], [Voit 2000] as v = axixj−bxk.
Its effects on the differential equations of the network are as follows: if we let
x˙i = fi(x1, ..., xn), i.e. if we model the derivative of the phosphorylated con-
centration of protein xi as a function of the state of (possibly) all proteins,
then, because the reaction de-phosphorylate xi, then x˙i = fi(x1, ..., xn)−v, and
similarly x˙j = fj(x1, ..., xn) − v. On the contrary, since the specific reaction
increases the phosphorylation of xk, we will have x˙k = fk(x1, ..., xn) + v.
The immediate consequence of this modeling assumption is that if we know
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that a simple quadratic reaction v = axixj − bxk is involved in a network,
then we know that the representation of the derivative of xi,xj ,xk will have a
specific quadratic and a specific linear term in the representation in (1). Only
the parameters of these terms will be unknown.
The more reactions we make available as targets of kinase inhibition, the
more indirect information we have about the details of the terms of the model.
In many models it is possible as well that the algebraic form of the reaction is
v = axixj − bxkxh, this does not affect the modular building of the network, or
our approach, but only the range of proteins affected.
One way to model kinase inhibition (see [Hornberg et al. 2005]) is to assume
suppression of a target reaction v, i.e. v will appear in the representation of
the derivatives of the relevant proteins concentrations multiplied by a kinase
suppression coefficient κ < 1.
This modeling of kinase inhibitors stems from the assumption that, what-
ever the current impact of a reaction on the network, a kinase inhibitor tar-
geting that reaction can only slow down its effect on the network in relative
terms. Clinical and biological evidences in cancer therapy suggest that the re-
sponse of patients is often limited by both the low efficacy of drug targeting
and by resistance mechanism that cancer cells evolve before and during treat-
ments. Nonetheless, many tumors are dependent (‘addicted to’) on specific sig-
naling nodes/pathways and even subtle reductions in the total amount of such
nodes can impair tumors homeostasis over time ([Sharma and Settleman 2007],
[Weinstein and Joe 2008]). Such evidences are the foundation of combinatorial
treatments for cancer and of our assumption that even just a relative, but con-
tinuous slowing down of a reaction can have important impact on the network.
Most kinase inhibitors discovered to date are ATP competitive and present
one to three hydrogen bonds to the amino acids located in the hinge region
of the target kinase, thereby mimicking the hydrogen bonds that are normally
formed by the adenine ring of ATP [Zhang et al. 2009].
Oftentimes kinase inhibitors cross-react, with various degrees of specificity,
either with other kinases among the 518 encoded in the human genome, or with
the abundant nucleotide-binding enzymes that are present inside cells. The
degree of kinase inhibitors selectivity depends on many factors such as their
concentration and cellular context. Biochemical and cellular assays are available
for the dissection of the specificity range of small molecules for various kinases,
but to date the evaluation of kinase inhibitor selectivity on an organismal level
remains a significant research challenge [Zhang et al. 2009].
Different models of inhibition of reactions can be easily implemented in our
method, for example forward rate kinase inhibition and backward rate kinase
inhibition would require κ to act only on the first or second term of the reaction
respectively. Since changes in κ in general do not affect to a large extent the
activity of any given individual node, in Section 3 we use κ = 0.1. Such value of
κ allows for detectable changes of trajectories, but it may lead in real systems
to unspecific inhibition.
Our discussion up to this point clarifies how the knowledge of a reaction in
the system can be used to build specific building blocks in selected differential
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equations of the unknown model. Next, we write down the heuristic description
of a modified augmented reconstruction algorithm that includes knowledge of
the reactors of a given set of reactions. The details of the algorithm are given
in Appendix 2.
Modified ASR Algorithm
Select a collection of potential target reactions vs = asxisxjs−bsxks , s = 1, ..., S.
Given the collection of all time measurements for each node n with n = 1, ..., N :
R1 Set up a representation matrix Z where each column corresponds to a
term of the right hand side of equation (1) (constant, linear, quadratic
and random). Set up a vector Yn that corresponds to the left hand side
of (1).
R2 Select the columns of Z that correspond to the target reactions involved
in the activity of the given node n.
R3 Perform augmented sparse reconstruction for Yn using only the columns
selected in step R2 to force those terms to have large parameters in the
overall representation. Subtract the contribution of the target terms from
the vector Yn.
R4 Perform augmented sparse reconstruction for the modified Yn using the
full representation matrix Z. Add back the the parameters of the target
terms found in the previous step to the corresponding parameters found
with the full matrix Z.
R5 Choose a threshold Tn. The reconstructed network equation for node n
will have only linear and quadratic terms that correspond to parameters
larger than Tn.
The modified ASR algorithmR1-R5 generalizes the algorithm in [Napoletani et al. 2008]
in such a way that, for each node, a preliminary augmented sparse reconstruc-
tion is performed only on the terms that are related to the reactions we selected
as potential kinase targets, if they have an impact on that node. After this
preliminary step, a full augmented sparse reconstruction is performed with all
potential linear and quadratic terms. We stress that only the reactors in the
targeted reactions need to be known, while the parameters of the reactions are
found by the modified ASR method automatically.
Note that we output a full model from the algorithm, rather than a list of
directed links to each node. This puts us in the position of testing our conjecture
that the augmented sparse reconstruction of a network can be homologous to
the reference network.
3 Partial Homology of Networks
With the algorithm described in the previous section, we can produce a recon-
structed network model of the reference EGF-R network that is very likely to
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include the reactions vs = asxisxjs − bsxks , s = 1, ..., S that we want to target
with kinase inhibitors with nonzero parameters as and bs.
Throughout the remaining sections, it is assumed that we have sets of 20
different noisy initial conditions for time courses of nodes of the network, and
that we sample each time course at 11 points in the interval [0, 11], with time
measured in minutes. This interval is acceptable because, after t = 11, most
nodes relax back to their steady state and they do not contribute to the under-
standing of the dynamics. Noise level for each time course is assumed to be at
most 10% of the maximum value of the points along the time course itself. This
setting gives us a time course microarray with 20 × 11 = 220 data points for
each of the 103 nodes in the reference EGF-R network.
This number of data points in the microarray is very small from the data
mining perspective, but it is large from the experimental, in vitro point of view.
However, it is within the limits of current experimental practice for reverse phase
protein arrays, see for example the study in [Nishizuka and Spurrier 2008] or
[Nishizuka et al. 2008]2.
If a specific experimental setting, or cell type, does not activate some path-
ways, it is likely that those pathways will not be detected, and their contribution
to kinase inhibition will not be measurable. Therefore, initial conditions of pro-
tein concentrations, corresponding to distinct cell states, should ideally be able
to explore as much of the dynamical range of the reference network as possible.
This can be achieved experimentally by varying growth factors concentrations,
e.g. EGF, across cell lines of different origins.
At the same time, we only need to detect homology according to our defi-
nition in Section 1, and we argue in this section that it is possible to generate
an homologous reconstructed network using the modified ASR algorithm even
when only very limited data are available.
In this paper, the time course microarray data used in the modified ASR al-
gorithm are simulated from the reference EGF-R network described in [Schoeberl et al. 2002].
The simulated initial time course microarray, and the modified ASR algorithm,
provide us with a candidate reconstructed network that is then compared to the
reference network3. Reference and reconstructed networks are simulated in the
MATLAB environment available at www.mathworks.com.
The choice of meaningful initial conditions for the time courses is complicated
by the fact that the copy numbers of individual proteins vary enormously, and
protein concentration varies with cell type and cell cycle stage, from less than
20000 molecules per cell for the rarest types to 100 million copies for the most
common ones. In the average mammalian cell some 2000 proteins are considered
to be relatively abundant [Alberts et al. 1994], [Lodish et al. 2000].
On the basis of these broad considerations, the initial conditions for the
2We mention here as well our work in preparation on adult stem cells, where the aggregate
data set generated by RPPA encompasses about 300 data points per node: Functional Protein
Network Activation Mapping of Adult Mesenchymal Stem Cells Differentiation, B. McCloud,
L. Liotta, E. Petricoin.
3 The values of the time courses are known to be positive, and this is enforced, for the
simulation of the reconstructed network, in the discrete differential equation solver.
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protein concentrations of the reference network are chosen to be random values
uniformly distributed in the interval [2000, 20000]. These values are assumed to
be the average number of copies of molecules per cell, and we are assuming that
different cell lines might have inherently diverse protein expression patterns.
The average number of EGF receptors is taken to be a random value in the
interval [1000, 10000] . EGF is selected to be a random value in the interval
[10−8, 10−7] to simulate varying degrees of EGF stimulation. Units are different
for EGF as this is a compound outside the cell and we measure it in gr/ml.
Remark 2: Even though this range of concentrations of each protein is rea-
sonable, the choice of initial conditions for concentrations is still not necessarily
biologically meaningful, since the relative distribution of the initial conditions
of the nodes with respect to each other is randomly selected. Yet we believe
that our choice reflects two basic assumptions that are necessary for the success
of our method, and that are indeed biologically meaningful: strong variability
of time courses, and measurable dynamical changes.
Remark 3: Note moreover that the size of the simulated time course mi-
croarray used in the modified ASR reconstruction is very small compared with
the volume of potential initial conditions, so that we are severely undersam-
pling the space of allowed initial conditions. Yet, we will see in the following
that these small data sets have predictive power when used to infer the degree
of inhibition of nodes with other initial conditions. Therefore it seems that ho-
mology of networks has some robustness with respect to potential variations in
the experimental setting, so that not every context relevant to a specific study
need to be probed for the application of our methodology.
Remark 4: Our analysis of the simulated EGF-R network model described
in [Schoeberl et al. 2002] is done assuming that the parameters of the network
are constant in the interval of time during which the time course microarray
is generated. This assumption seems reasonable because, even in practice, the
time courses over which the microarray data are generated are limited to a
time scale of days, and in the scenario of our simulations time courses are
taken over only 11 minutes. Moreover, in case of translating the modified ASR
method to a real world situation where we may seek a therapy for a disease or a
pathophysiological state, the time to disease progression and hence to a potential
change in the underlying network, is measurable in a time scale of months
[Ernst et al. 2008]. We conclude that during the time required for applying the
modified ASR method to biological samples microarray dataset, the networks’
parameters can be considered reasonably constant.
For clinical purposes, not all nodes are of interest. For example in the refer-
ence model of EGF-R, x51 (doubly phosphorylated MEK) and x59 (doubly phos-
phorylated ERK) are particularly significant targets [Schoeberl et al. 2002]. In
this paper we are interested in showing the global effect of a wide choice of kinase
inhibitors on the ensemble of all network nodes, to determine a global measure
of homology for the reference and reconstructed networks, with limited data
available for the reconstruction of the homologous network. At the same time
we focus on at least one node (node 31, or Shc) that is particularly amenable
to our techniques, and that has biological relevance.
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To check the global effect of kinase inhibitors on the network, we select a
set S1 of 19 reactions to target with inhibitors, on the basis of their position
along the EGF-R signaling cascade, in order to comprise both upstream and
downstream molecular events that span the entire signal transduction cascade
from top (EGF-R docking sites) to bottom (MEK or ERK phosphorylarion).
The set of reactions S1 is comprised by 9 pairs of reactions for surface and
internalized receptors plus a single degradation reaction4.
Although the function of internalization is not the same for all the receptors,
it has been demonstrated that EGF-R signals through internalized receptor com-
plexes. A clear correlation between surface and internalized molecules has not
been discovered since internalization also causes receptor deactivation. Impor-
tantly, [Schoeberl et al. 2002] demonstrated that under certain circumstances,
such as low EGF concentration, the internalization rate is a critical factor in
EGF-R signaling. We took into account both the surface and internalized reac-
tions since both contribute to the overall signaling and, at least for the EGF-R
system, molecules exist already in the clinics which would allow for the selec-
tive targeting of surface receptor only (Cetuximab monoclonal antibody). This
selective targeting is not feasible for many drug targets that are currently ex-
ploited for cancer therapy, but we can still treat in theory the internalized or
non-internalized versions of each reaction as if they were two distinct reactions,
and hence evaluate their relative impact upon inhibition. Notably, a single node
that signals through both internalized and non-internalized counterparts could
be inhibited by blockade of both reactions. Similarly, if the internalized version
of a node is not affecting the signaling output, the reconstructed system will
suggest inhibition of the non-internalized reaction.
We also note that our results do not depend essentially on selecting pairs of
internalized and non-internalized reactions. In Figure 4 we summarize results
for three other sets of reactions for which there is not extensive matching of
internalized and non-internalized versions of the same reaction. This scenario
is the most general one, applicable also to networks other than the EGF-R
signaling network, and therefore we will treat internalized and non-internalized
version of reactions as if they were distinguishable.
In Figure 1 we can see an instance of the effect of kinase inhibitors on both
reference and reconstructed networks. The top plot shows the change of time
course of node 66 of the reference EGF-R network when reactions v41 and
v83 are inhibited with κ = 0.1. The bottom plot shows the corresponding
change of time course for the 66th node of the reconstructed network. The
dynamics of reference and reconstructed networks are just marginally similar for
the node in Figure 1. The important point is that we do observe a measurable
change of time courses due to the inhibition of those two reactions. Indeed,
we choose to display node 66 only because its displacements for reference and
reconstructed networks are of similar order of magnitudes and amenable to a
direct graphic comparison. The similarity of the time courses is, for other nodes,
4 The specific reactions that we select in S1 are: v19, v66; v20, v67; v23, v70; v27, v74;
v29, v76; v41, v83; v45, v87; v47, v89; v55, v97; and v60. Refer to [Schoeberl et al. 2002] for
an actual description of these reactions.
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(a) Reference Network
Figure 1: An instance of relative concordance of the magnitude of displacement of
trajectories for reference and reconstructed networks due to a specific pair of kinase
inhibitors. Dashed curves are the trajectories with inhibitors on, while solid curves
are the trajectories without inhibitors. The top plot shows the effect of inhibition of
reactions v41 and v83 on the 66th node of the reference EGF-R network. The bottom
plot shows the corresponding trajectories for the same node 66 of the reconstructed
network. The dynamics of reference and reconstructed networks are just marginally
similar for this node. The important point is that we do observe a measurable change
of time courses due to the inhibition of the reactions for both networks.
even less pronounced than what we observe in Figure 1 for node 66, or it may
happen that the change of time course of a node, due to control, is several
order of magnitudes smaller for the reconstructed network. This is expected,
since we are using an incredibly small amount of data to build the reconstructed
network and we cannot expect similarity in the actual trajectories generated by
this coarse approximation. As an aside, it is not surprising that inhibition of
reactions v41 and v83 would naturally lead to the modulation of node 66 (and
35, not shown). In fact, reaction v41, [(EGF − EGFR∗)2 − GAP − Shc∗] +
[Grb2 − Sos] ↔ [(EGF − EGFR∗)2 − GAP − Shc∗ − Grb2 − Sos], and its
internalized counterpart v83, represent the recruitment of adaptor proteins to
the activated receptor. These reaction are directly upstream of node 35 and
66, which are the canonical and internalized versions of the same node (i.e.
(EGF − EGFR∗)2 − GAP − Shc∗ − Grb2 − Sos). Interestingly, it has been
shown that treatment of leukemia cells with a specific Grb2-SH3 (Growth factor
Receptor-Bound protein 2 - SH3 domain) inhibitor that disrupts the Grb2-
Sos (Son of Sevenless) complex, has dose-dependent cytotoxic effects, although
not comparable with the efficacy of Gleevec in chronic myelogenous leukemia
[Ye et al. 2008].
In Figure 1, note also that the sign of the change due to control is the op-
posite in the two networks. In Appendix 1 we show that this is a common
occurrence with this method. This sign switching may potentially be lessened
13
by cross-validating parameter estimation for the different nodes affected by the
targeted reactions. We stress that our goal is not exact trajectory reconstruc-
tion, but only an estimate, using the reconstructed network, of how much the
magnitude of trajectories of the reference network are changed when kinase
inhibitors control is switched on.
To achieve this goal, we propose the following estimation of the change
of the trajectories due to kinase inhibitors control: (a) We randomly
select several initial conditions for concentrations in the same wide region used
to generate the initial time course microarray of the reference system. (b) We
simulate reference network and reconstructed network with each of these initial
conditions for a fixed length of time, long enough for most time courses to relax
to their steady state. (c) We perform these simulations with the target kinase
inhibitors switched on, and then with the kinase inhibitors off. (d) For each
node, we compute the maximum pointwise distance between trajectories with
same initial conditions and with control on and off respectively, over the whole
time interval used in the simulations. (e) The maximum pointwise distance for
each node is divided by the maximum value of the trajectory of the same node
in the reference network, with control switched off. (f) Finally, we measure the
median of the scaled displacement for each node variable, with respect to the set
of initial conditions, as a statistically significant measure of node displacement
due to control.
We call the quantity generated by the procedure (a)− (f) the median scaled
maximum pointwise displacement of trajectories of a node due to the specific
choice of control kinase inhibitors, sometimes we will refer to this quantity
simply as median scaled displacement.
Remark 5: We consider the median since most of the time the scaled
displacement has very similar behavior for most initial conditions, but there
is rarely a small number of initial conditions that may lead to divergent time
courses for some nodes in the reconstructed system, making the mean too sen-
sitive to these outliers.
In Figure 2 we plot the magnitude of the median scaled pointwise displace-
ment of node 31 with respect to an ordering of 190 different kinase inhibitor
combinations, where only one or at most two reactions of the set of 19 reactions
S1 (described in footnote 4) are inhibited at the same time
5. Each kinase in-
hibitor coefficient κs, s = 1, ..., 19 is allowed to be either 1 (no inhibition) or 0.1
(high kinase inhibition), This combinatorial constraint is in line with current
experimental protocols, i.e. to allow only two kinase inhibitor coefficients to be
different from one for each possible combination. In this scenario an important
problem is to find the optimal two kinase inhibitors to choose from a possibly
large collection of inhibitors. More complex combinatorial scenarios can be en-
visioned as well, with several kinase inhibitors used at the same time. Note
that generally a kinase inhibitor is considered useful if it changes the phospho-
rylation of a target by a significant amount. Our choice of κs equal to 0.1 for
5 The total of 190 combinations is the result of taking every combination of 1 out of 19
reactions (19 such combinations) and every distinct combination of 2 reactions out of 19 ( 171
such combinations).
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Figure 2: In this plot we show a case in which the shape of the median scaled max-
imum displacement curve is very similar for reference and reconstructed networks for
high values of displacement. The blue starred line gives the median scaled maximum
displacements for the 31th node of the reference EGF-R network. Each point on the
horizontal axis corresponds to one among 190 different pairs of kinase inhibitors com-
binations. The red starred line gives the median scaled maximum displacement curve
for the same node in the reconstructed network. Curves are scaled to have norm equal
to one for comparison purposes. Note the reversal of sign of the median displacement
curves for large displacement values.
individual reactions increases the chance that we observe relative displacements
of the nodes of the reference network in the order of 10− 20%.
Remark 6: It is implicitly assumed in the model that the kinase inhibitors
are specific at these concentrations. Notwithstanding the strict 100-fold speci-
ficity criteria used during the screening that companies usually perform for
kinase inhibitors selection process, many inhibitors show various degrees of
off-targets, depending either on their concentration or on the cell type. In-
terestingly, some approved drugs (e.g. sunitinib, dasatinib) had relatively low
selectivity but are nevertheless effective for clinical use. Knowledge of target
profiles should allow careful evaluation as to which drug or drug combination
should be used in a particular situation to better exploit each drugs full potential
[Johnson 2009].
There is a striking concordance of the shape of the two median scaled dis-
placement curves in Figure 2 for large values of median scaled displacement,
even though the magnitude for each individual kinase inhibitor combination
can be vastly different and indeed the magnitude of the median scaled displace-
ment for the reconstructed network can be far lower that the one of the reference
network for many nodes, even when there is very high concordance of the shape
of the median scaled displacement curves. The observed concordance suggests
that the median scaled displacement curve of the reconstructed network can be
used to infer the corresponding curve for the reference network.
We choose to focus our attention on the 31st node of the reference network
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as this represents Shc protein (Src homology 2 domain-containing transforming
protein 1 or SHC1), an important potential target of effective therapies that
acts upstream of the Ras oncogene. More specifically, isoforms p46Shc and
p52Shc, once phosphorylated, couple activated receptor tyrosine kinases to Ras
and are implicated in the cytoplasmic propagation of mitogenic signals. Thus
isoform p46Shc and isoform p52Shc may function as initiators of the Ras signal-
ing cascade in various non-neuronal systems [Migliaccio et al. 1997]. Differently
from other isoforms, p66Shc does not mediate Ras activation, but is involved
in signal transduction pathways that regulate the cellular response to oxidative
stress and life span. Moreover p66Shc acts as a downstream target of the tumor
suppressor p53 and is indispensable for the ability of stress-activated p53 to
induce elevation of intracellular oxidants, cytochrome c release and apoptosis.
In fact, p66Shc competes with other Shc isoforms for binding to the activated
receptor complex and skews the signal transduction towards apoptosis. Finally,
the expression of p66Shc has been correlated with life span, therefore conferring
to such a node a great biological importance [Ulivieri 2010]. The ERK path-
way (Extracellular Signal-Regulated Kinase), which regulates cell proliferation,
is initiated through recruitment to the activated EGFR of a protein complex
that contains Shc itself and GRB2 adaptor proteins bound to the exchange
factor Sos. Subsequently, Ras is activated by GTP hydrolysis thus leading to
ERK phosphorylation and cell proliferation. Ras is one of the most important
oncogenes whose deregulation inevitably confers a proliferation advantage to
neoplastic cells. In fact, somatic KRAS mutations are found at high rates in
leukemias, colon cancer, pancreatic cancer and lung cancer, whereas KRAS gene
mutation is predictive of treatment response to anti-EGFR therapy in colorectal
cancer patients [Janakiraman et al. 2010]. It is conceivable that the high degree
of homology of displacement curves observed for node 31st (Shc) is due to its
critical position along the EGF-R signaling and to the major role of the protein
complex that is involved in regulating Ras activity. Nonetheless strong homol-
ogy of median scaled displacement curves has been observed for downstream
events (node 58, i.e. ERK-P -MEK-PP ), or other nodes that are not in direct
proximity to EGF-R activation (node 38, i.e. Shc∗-Grb2-Sos). Therefore our
method is capable of recapitulating network interactions without specific biases
to their location across the network.
In general, the displacement curves tend to agree only partially and only
for the largest displacements values. We also stress the fact that often (but
by no means always, see Appendix 1) the sign of the displacement is different
for the reference network and the reconstructed network, even when we have
highly correlated absolute values of the displacement curves, this is potentially a
problem because the sign of the displacement will determine whether the control
acts as a inhibitor or a enhancer of the target node.
It is likely that the cause for the sign switching is the inability of the re-
stricted l1 optimization in step R2 of the modified ASR algorithm to detect
the proper parameter in the presence of noise, even when we enforce that such
parameter should be present. Regardless, the displacement curve of the recon-
structed network will be able to identify combinations of kinase inhibitors that
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Figure 3: In Figure 3(a) we show three histograms of the Spearman correlation of
the absolute value of corresponding median scaled maximum displacement curves in
the reference and reconstructed network. Each histogram correspond displacement
curves generated with one of three different choices of initial time course microarrays
as input for the modified ASR algorithm. In Figure 3(b), we show the histograms
of the Spearman correlations of the displacement curves of the nodes of the reference
network, and randomly permuted versions of the displacement curves of the nodes
of the reconstructed networks. All displacement values below 10% of the maximum
value of each displacement curves are set to zero before computing the Spearman
correlations.
have high impact on the node and in the following we compare only absolute
values of median scaled displacement curves.
For example, we can compare the Spearman’s rank correlation [Gibbons and Chakraborti 2003]
of the absolute value of displacement curves for corresponding nodes in refer-
ence and reconstructed networks. A high Spearman’s rank correlation would
indicate a very good agreement of the pattern of increase and decrease of large
displacements for a given node. In Figure 3(a) we show three histograms of
Spearman correlation of corresponding median scaled displacement curves for
reference and reconstructed networks. All of them are obtained assuming that
the set S1 of reactions (see footnote 5) is the target of kinase inhibitors, and
that the modified ASR algorithm is given as input three different sets of time
course microarrays, i.e. three completely different sets of initial conditions and
dynamical evolutions of the EGF-R network. To avoid the impact of relatively
small displacement values, all displacement values below 10% of the maximum
value of each median scaled displacement curves are set to zero before computing
the Spearman correlations. Note the very long right tail of large correlations,
indication of excellent agreement of displacement curves for several nodes. Such
tail is completely absent when, in Figure 3(b), we compute the histograms of the
Spearman correlations of the median scaled displacement curves of the nodes of
the reference network, with randomly permuted versions of the median scaled
displacement curves of the nodes of the reconstructed networks.
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4 Homologous Control of Nodes
Our analysis so far gives a sense of the distinctive homology of reconstructed
and reference networks. Our final goal is to use homology to obtain a nearly
optimal kinase inhibitor combination, and we propose the following strategy:
Homologous Control
C1 Given a set of trajectories in a signaling network, and a set of reactions
to be inhibited, use the modified ASR algorithm in Section 2 to obtain a
reconstructed, potentially homologous network.
C2 Consider a large set of kinase inhibitor combinations that satisfy some give
constraint. For each kinase inhibitor combination generate time courses of
the reconstructed network for a variety of biologically meaningful initial
conditions.
C3 Generate the median scaled displacement curve for a target node pro-
tein. Identify the position of the few largest values of the median scaled
displacement curve for the reconstructed network. The corresponding ki-
nase inhibitor combinations are candidates for nearly optimal suppres-
sion/enhancement of the target node in the reference network.
Several possible choices of constraints could be enforced in step C2 of this algo-
rithm. For example, in personalized therapies we could ask for the combination
of kinase inhibitors with a minimum total norm of the corresponding kinase
inhibitor coefficients κ, to reduce total amount of inhibitors and therefore to
avoid toxicity and loss of specificity.
In the following, we continue to explore the experimental protocol used to
generate Figures 2 and 3 in which only two reactions at the time are inhibited.
Recall that since we have 19 possible kinase inhibitor targets, there are a total
of 190 distinct pairs and singlets of kinase inhibitor therapies.
In our simulations there is remarkable agreement of the location of large
peaks of the median displacement curves for reference and reconstructed net-
works, so that it seems possible to use the largest median displacement values
of the reconstructed network to predict the likely location of near-optimal com-
binatorial kinase inhibitions.
We cannot expect full overlapping of locations of large peaks and therefore
we suggest the following definition of near-optimality of kinase inhibitor
combinations: We assume that we found near-optimal kinase inhibitor com-
binations if the locations of the top three maxima in the median scaled displace-
ment curve of a node of the reconstructed network overlaps with the location of
large median scaled displacement values of the corresponding node in the refer-
ence network. A large displacement is defined here as a value that is a large
percentage, say 80%, of the mean of the largest 3 displacement values of the
given node in the reference network.
Remark 7: Note that we use, as a benchmark of success, the mean of the
largest three median displacement values, rather than the absolute maximum
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displacement. We decided for this criterium since in principle the absolute value
may be so large compared to the other displacements values that there may not
be other significant kinase inhibitor combinations with displacement values close
to the maximum.
Since the scaled displacement curves of many nodes of the reconstructed
network are not carrying any useful information on the corresponding nodes of
the reference network, we need to find a way to filter the most useful nodes of
the reconstructed network.
Our understanding is that the larger the displacements of a node in the re-
constructed network, the more likely the chance that they convey some useful
information about the corresponding displacements of the node of the reference
network. This is the case because large displacements probably indicate an
increased sensitivity of the reconstructed network to specific kinase inhibitors.
The following procedure defines quantitatively a notion of large displace-
ments: we take the median nonzero displacement value for each node in the
reconstructed network, and then the mean of these medians across all the nodes
in the network. We threshold to zero all displacements that are below this value,
so that we retain only displacement values that are large relatively to the overall
activity of the network.
After removing small displacements with the previous procedure, we filter
the nodes in the network by retaining only nodes that have the mean of the
remaining nonzero scaled displacements above increasing large threshold values.
Note that these threshold values are dimensionless, since they relate to the scaled
displacements that are by definition dimensionless.
This filtering of nodes is very stringent, in the sense that only a few nodes are
left by this process, and yet it is quite effective at identifying those displacement
curves in the reconstructed network that partially correlate to the corresponding
displacement curves of the reference network. In particular, in Figure 4(b), the
dashed curves shows the number of nodes of the reconstructed network that
have mean of the large nonzero median displacement values above the threshold
specified on the horizontal axis. Again, we show our results for three different
sets of time course microarrays given as input into the modified ASR algorithm.
The dashed curve in Figure 4(a) shows the ratio of nodes for which we
identify near-optimal kinase inhibitor combinations (as defined above), as a
function of the same threshold as in figure 4(b). We reach at least a 0.5 success
ratio, meaning that, given sufficiently high threshold, for 50% of the nodes
that are not filtered out by the threshold, we can identify near-optimal kinase
inhibitor combinations. The catch is of course that only a few nodes display such
marked homology in the reconstructed median scaled displacement curve. The
0.5 ratio mark is reached when the threshold leave respectively 10, 6, and 2 nodes
for the three time course microarray inputs to the modified ASR algorithm. On
the other hand, it is striking that we can eventually reach 100% success ratio
(respectively for 6 and 3 nodes) for two of the microarray inputs .
The solid curves in the same plot 4(a) shows the average percentage of
nodes for which we identify near-optimal kinase inhibitor combinations when
19
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Figure 4: Plots (a) and (b) refer to the set of 19 reactions S1. In plot (b) the three
dashed curves shows the number of nodes of the reconstructed network that have mean
of large median displacement values above the threshold specified on the horizontal
axis. In plot (a), the three dashed curves shows the ratios of nodes for which we iden-
tify near-optimal kinase inhibitor combinations, as a function of the same threshold.
The solid curves shows the average ratio of nodes for which we identify near-optimal
kinase inhibitor combinations when the sequence of median scaled displacements for
the reconstructed network has been randomly permutated (average computed over 100
permutations). Each color corresponds to the analysis of one of three different choices
of initial time course microarrays as input for the modified ASR algorithm. Plots (c),
(e), (g), and (d), (f), (h) repeat the same analysis as in plots (a) and (b) respectively,
for three more sets of kinase inhibitors (see footnote 6).
20
the sequence of median scaled displacements for the reconstructed network has
been randomly permutated (average computed over 100 permutations). Near-
optimality for the random scrambling of the data is much lower, especially for the
nodes left by higher threshold values. The mean of the ratio of nodes for which
we find near-optimal combinations in the case of random permutation of the
reconstructed displacement curves in Figure 4(a) is only around 0.1 (computed
across all threshold values and all three time course microarrays inputs). For
nodes selected with high values of threshold, our method is at least about 5
times more accurate than a random selection of kinase inhibitors in finding
near-optimal combinations, and up to 10 times more accurate for some selected
nodes with two microarray inputs.
To put things in perspective, with the randomly permuted scaled displace-
ments, on average it would be necessary to select randomly between 18 and
30 kinase inhibitor combinations (depending on the microarray input instance)
to make sure that we have at least a 0.5 success ratio, reachable with only 3
kinase inhibitor combinations by the homologous control scheme. This repre-
sents a large potential saving, due to the data-based narrowing of combinatorial
possibilities, in the search for appropriate kinase inhibitor therapies.
Figure 4(c,d), 4(e,f), 4(g,h) show the results of the same analysis performed
in Figure 4(a,b), for three other selections of 19 kinase inhibitors 6, and sev-
eral distinct initial microarrays. The main criterion underlying the choice of
reactions has been the availability, for most of the selected reactions, of in-
hibitory drugs that might be used to block the downstream signaling. Several
example exist that have either passed FDA approval or are currently in clini-
cal trials, like monoclonal antibodies or small molecules inhibitors that target
EGF-R (Cetuximab and Gefitinib, respectively) and small molecule inhibitors
of the Raf/MEK/ERK axis (Sorafenib). The number of reactions that satisfy
this experimental plausibility criterium is relatively small in the cited EGF-R
network, and there is a certain degree of overlapping among these sets.
Note that the success curve is not monotone for one instance (red dashed
line) in Figure 4(c), indicating that some strongly homologous nodes are actually
removed as the threshold value increases. This raises the hope that even better
success rates could be achieved with more sophisticated threshold processes. In
particular, it may be beneficial in some cases to have an adaptive threshold
that is a variable multiple of the mean of medians used to pre-condition the
displacement curves. This may allow for a larger number of nodes to be retained.
The success rate of homologous control is, for high enough threshold value,
at least 50% for reactions analyzed in Figure 4(c,d) and Figure 4(e,f). Figure
4(g,h) is, instead, significantly different, in that, for one instance of microarray
6The reactions selected for inhibition corresponding to Figure 4(a,b), 4(c,d), 4(e,f), 4(g,h)
are respectively: (S1) v19, v20, v23, v27, v29, v41, v45, v47, v55, v60, v66, v67, v70, v74,
v76, v83, v87, v89, v97; (S2) v1, v2, v3, v10, v16, v28, v29, v36, v37, v45, v46, v47, v48, v64,
v75, v94, v95, v126, v130; (S3) v1, v2, v12, v23, v27, v33, v34, v36, v45, v53, v56, v74, v76,
v78, v89, v97, v111, v129, v130; (S4) v1, v3, v11, v18, v22, v26, v29, v33, v39, v42, v44, v52,
v65, v67, v75, v88, v96, v128, v148. Refer to [Schoeberl et al. 2002] for an actual description
of the reactions.
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(blue dashed curves) no displacement curve of the reconstructed network passes
the filtering process. A careful analysis of the different selections of kinase in-
hibitors shows that, while their distribution in the network is very similar, the
actual parameters of the reactions selected for inhibition are significantly differ-
ent for Figure 4(g,h). Specifically, the number of large (bigger than one) forward
and backward kinetic rates is about a third of the corresponding number of large
kinetic rates in the other three selections of 19 kinase inhibitors. This observa-
tion may justify the failure of our method for one instance of initial microarray
and it is an important point that both shows the limits of our technique, and
suggests that, for the method to be eventually applied in practice, care should
be made to select, when possible, kinase inhibitors that act on relatively fast
reactions. Most nodes that show sizable displacement curves are likely to be
close to these fast reactions, when targeted by kinase inhibitors.
Remark 8: Another point that needs clarification is the extent to which
the modified ASR method is essential to the success of the identification of near-
optimal combinations. In other words, is it necessary to know the nodes that are
involved in each of the 19 reactions that we target for inhibition? The answer
is affirmative: without knowledge of the presence of these reactions, many of
the relevant parameters are overlooked by the standard ASR algorithm, in the
sense that either they are not found, or their value is underestimated. We find
ourself in a scenario very similar to one of the instances of Figure 4(g,h), where
very few nodes in the reconstructed network have any response to the kinase
inhibitors (not shown). In general, we expect the performance of the method
to improve with larger sets of kinase inhibitors and to worsen with smaller sets.
However, large sets of kinase inhibitors are likely to arise in the experimental
setting and this is the scenario where the method should work best.
5 Discussion and Conclusion
Our method for homologous control is an attempt to develop a signal processing
approach to network dynamics and it has the potential of greatly reducing
the experimental load necessary to find near-optimal combinations of kinase
inhibitors for a list of potential target reactions. Its strength is in the ability to
work with very limited, noisy data and with networks that have a large number
of nodes, comparable with realistic time course microarray data. In this last
section we would like to point out several broad areas for further development
that are intimately related to the limitations of current experimental protocols
for measuring node activity of signaling networks.
Our approach is dependent on the choice of a region R where we select the
initial conditions, and on the duration T of the time series, so that we could
say that the notion of homologous systems and signal processing of networks is
transient based, i.e. it depends on the choice of the cylinder R × [0, T ]. This
raises some issue on the stability of the homology, if we run the reference system
for a time T , how long should we run the reconstructed system?
One characteristic of the reconstructed network is that its dynamics displays
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slower changes when compared to the reference network, probably because the
parameters of each term in the equations are not as large as the true parameters,
so that the rate of change of nodes will generally be different for the reference
network and the reconstructed one. Nevertheless, the type of curves that we
observe are usually transients with eventual relaxation, so that T can be chosen
for both networks as the time such that either the trajectories of the networks
have relaxed to their steady state, or they show consistent divergence.
A possible strategy to improve parameter estimation for large networks is
to run the reconstruction algorithm several times with different choices of the
random terms; collect for each node the terms that display significant activity
for at least one repetition of the reconstruction algorithm; repeat one last time
the reconstruction for each node, only using the nodes previously selected as
significant. This bootstrap version of the reconstruction algorithm may improve
homology with the reference system.
An important question is to determine how infrequently we can sample the
trajectories of a network and infer a well behaved reconstructed network that
is homologous to the reference network. In some sense, we need a sampling
theory of networks; note that the sampling is done for the trajectories, and it is
a signal processing operation, but the notion of well behaved system is essential
a dynamical one.
To gain a sense of the difficulty of this endeavor, consider that the tra-
jectories’ sampling rate used in this paper clearly do not allow for high true
positive rates and low false positive rates of identification of parameters in the
reconstructed network. Significant noise is observed in the network parameters’
estimation, even in the parameters of the reactions selected for kinase inhibition.
Indeed, the actual trajectories generated by the reconstructed network do
not need to show any strong resemblance to those of the reference network.
The very notion of homologous networks is designed to be useful exactly when
we undersample the network trajectories so severely that we do not hope for
a proper network reconstruction. As we showed in this paper, as little as 220
data points per node are sufficient to obtain partial homology, possibly because
the sensitivity of the initial dynamics of the trajectories to kinase control may
be predictive of the sensitivity over the full transient leading to relaxation to
the steady state. The theoretical determination of the relation between number
of samples per node and network homology will require extensive study and
comparison of several biologically meaningful models of pathways.
It is also crucial to understand the performance of our method when dealing
with incomplete networks where only a portion of the nodes is measured. We
tested, for example, the nearly-optimal kinase prediction algorithm C1-C3 on
a module of the EGF-R model comprising only 16 variables, with only two reac-
tions selected for kinase inhibition, and we were indeed able to observe homology
for several nodes even though many nodes were subject to large feedbacks from
unmeasured nodes7
7In this simulation (data not shown) we used 550 data points, and initial condition for
each node were kept very low for this simulation, while EGF was very large.
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It is yet to be seen whether a random choice of a subset of nodes belonging
to a pathway are sufficient to achieve homologous control. Of course, for our
method to make sense, at least all nodes involved in reactions to be inhibited
and the target node must be measured. We need to perform a detailed study
in which we identify the minimum number of variables (and their distribution)
that need to be measured to achieve homologous control.
The final goal of our approach is the experimental validation of homologous
control over a broad range of signaling networks in defined biological contexts
such as cell proliferation, survival and differentiation. The availability of hun-
dreds chemical compounds with known specific inhibitory activity allows to test
the efficacy of the predicted near-optimal kinase inhibitor combinations into
cell line models. In particular, it is possible to exploit cancer cell lines ob-
tained from diverse types of tumor and to train the modified ASR method with
reverse-phase protein microarray data containing time-courses for each cell line
under serum addition or hypoxic stimuli. The molecular dynamics driven by
such conditions would allow a validation of the in silico reconstructed network
in a specific and biologically meaningful context. The combinations of inhibitors
that are found by our method in this scenario could then be tested in vitro (and
eventually in vivo in immunodeficient mice) to understand their ability to affect
proliferation and survival mechanisms of tumor’s cells. Such an approach has
a great potential in the identification of novel therapeutic strategies for can-
cer. We stress moreover that there is no technical reason to restrict homologous
control strategies to the analysis of the EGF-R signaling network, or even to
protein signaling networks. A more general choice of terms for the model in
equation (1) would allow our method to be tested for multiscale heterogeneous
systems, where genomic, proteomic and metabolic compounds are related in a
single network.
Acknowledgments
The authors acknowledge the support of the College of Science at George Mason
University and the Istituto Superiore di Sanita`. They also would like to thank
Daniele C. Struppa for many useful discussions and the anonymous referees for
their constructive remarks.
Appendix 1: Sign Concordance and Sign Switch-
ing
One difficulty summarizing the qualitative properties of displacement curves
described in Section 3 is the tremendous variability of the individual nodes of
the network. However, it is clear that sign switching and sign concordance of
the displacement curves for high displacement values are both common, and not
due to random effects.
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For example, in Figure 5(a) we show the number of kinase inhibitor combi-
nations, out of the total 190 combinations used in the protocol of Figures 2 and
3, that display opposite sign, as a function of a threshold on displacement curves
of both reference and reconstructed networks. For each node, the threshold sets
to zero all displacements that are below the percentage of the largest displace-
ment value denoted in the ordinate axis. Red curves are for the 5 nodes that
have the highest number of combinations with sign switching. Blue curves are
generated in a similar fashion, but after the median scaled displacement values
have been permuted within the displacement curve of each node.
Note the very distinct behavior at the 20% threshold level between true and
randomized curves in Figure 5(a). Instead, Figure 6(a) shows, for each node
of the reconstructed network, the ratio of nonzero median displacement values
that display sign switching with respect to the reference network, in the case of
a 20% threshold. Many nodes, at this threshold level, exhibit large percentages
of sign switching.
Remark A1: We stress that this sign switching is by no means consistently
observed for all nodes, or for specific groups of kinase inhibitor combinations.
For example, the kinase inhibitor combinations corresponding to indexing from
85 to 100, shown in Figures 2 to have vigorous control on at least a node of
the network, have roughly the same number of nodes that display uniform sign
switch and uniform sign concordance for large displacement values. If we study
sign concordance rather than sign switching, a very similar qualitative behavior
as in Figures 5(a) and 6(a) is observed, as can be inferred from Figures 5(b)
and 6(b).
In Figures 5(c) and 6(c) we follow essentially the same procedure as the
one that we used to explore sign switching, but focusing on the concordance of
nonzero displacements. In Figure 5(c) we show the number of kinase inhibitor
combinations, out of the total 190, that display concordance of nonzero dis-
placement values, as a function of the same threshold on median displacement
curves of both reference and reconstructed networks used in Figures 5(a) and
5(b). Red curves are for the 5 nodes that have the highest number of combina-
tions with corresponding nonzero median displacement values. Blue curves are
generated from permuted median displacement curves.
In Figure 5(c) we see distinct behavior between real and randomized data es-
pecially around the 40% threshold level. The fact that this percentage is higher
than the one observed for the analysis of signs shows that sign concordance
and sign switching are more statistically significant than nonzero concordance
for lower threshold. Figure 6(c) shows, for each node, the ratio of nonzero
displacement values for the reconstructed network that is matched by nonzero
displacement values for the corresponding node of the reference network, at the
40% threshold level. Many nodes, at this threshold level, exhibit almost com-
plete overlapping of the nonzero displacement values of reconstructed network
with (some of) the nonzero displacement values of reference network.
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Figure 5: Red starred curves in Figures 5(a), 5(b), 5(c) shows the number of kinase
inhibitor combinations of the 5 nodes of reference and reconstructed networks that
display respectively the largest: 5(a) sign switching; 5(b) sign concordance; 5(c) con-
cordance of nonzero median displacement values. Blue starred curves are generated in
a similar fashion, but after the median scaled displacement values of the reconstructed
network have been permuted within the displacement curve of each node. Curves are
plotted as functions of a threshold on displacement curves of both reference and re-
constructed networks. For each node, the threshold sets to zero all displacements that
are below the percentage (of the largest displacement value) denoted in the ordinate
axis.
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Figure 6: Figures 6(a), 6(b), 6(c) show, for each node of the reconstructed network,
the ratio of nonzero median displacement values that display respectively: 6(a) sign
switching at the 20% threshold level; 6(b) sign concordance at the 20% threshold
level; and 6(c) concordance of nonzero displacement values at the 40% threshold level.
For each node, the threshold sets to zero all displacements that are below the given
percentage of the largest displacement value.
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Appendix 2: Recursive Augmented Sparse Re-
construction with selected target reactions
In this appendix we give details of the recursive augmented sparse reconstruc-
tion algorithm to be used in the presence of target reactions. Suppose we are
given N node variables from a network and that for each variable it is possi-
ble to generate R trajectories Xn,r r = 1, ..., R with different initial conditions,
uniformly sampled at L points. We build now the left hand side of (1) and the
individual terms in the right hand side.
Call X¯n,r the vector Xn,r(t) −Xn,r(t0) where t takes all L sampled values.
For a given vector g(t), t = t0, ..., tL, let I(g) be the vector whose l-th component
is the sum
∑l
i=0 g(ti).
Write Yn = [X¯n,1, ...,X¯n,R], Gn = [I(Xn,1), ..., I(Xn,R)], n = 1, ..., N , Gij =
[I(Xi,1Xj,1), ...,I(Xi,RXj,R)]. Finally, let J denote the unit vector with same
length as Yn.
Select a collection of potential target reactions vs = asxisxjs − bsxks , s =
1, ..., S. The basic process to identify the links among the nodes is the following.
For each node n with n = 1, ..., N :
R1 Choose an attenuation coefficient βq for the quadratic terms Gij . Let ng,
g = 1, .., G, be discrete random vectors normally distributed scaled to have
norm 1. Denote by | | the 2-norm of a vector and let Gˆl be the matrix
whose columns are all the vectors Gi|Gi| , Gˆq be the matrix whose columns
are all possible vectors
Gij
|Gij |
. Let NG be the matrix whose columns are
the random vectors ng scaled to have norm 1. Choose G large enough to
have the matrix Z = [JGˆl, βqGˆq, NG] with small condition number (say
less that 102).
R2 Set a temporary representation matrix M , for each s = 1, ..., S, if the
node n belong to the set {is, js, ks}, add the vectors
Gks
|Gks |
and
Gisjs
|Gisjs |
as
columns to the matrix M .
R3 Let ZM = [M NG]. Find the minimal l1 solution to the underdetermined
system Yn = ZMαM . Let αM be the restriction of α to the columns of
M , set Yn = Yn −MαM .
R4 Find the minimal l1 solution to the underdetermined system Yn = Zα. If
in partR2 we generated a nonzero matrixM , then add to the components
of α associated to the columns ofM the corresponding components of αM .
R5 Choose a threshold Tn and let αTn be the coefficients in α larger than
Tn. The reconstructed network equation for xn will have only linear and
quadratic terms that correspond to coefficients in αTn , and their coeffi-
cients will be the coefficients of αTn divided by the norm of the corre-
sponding |Gi|, if a linear term, and |Gij | if a quadratic term.
In [Napoletani et al. 2008] we showed that there is considerable flexibility
in the choice of the number G of random terms and in the choice of the
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attenuation coefficient βq; in this work we use G = 1500 and βq = 0.8.
The threshold Tn that selects the parameters to be used in the recon-
structed network is taken to be a very low 2% of the maximum magnitude
parameter for the corresponding node. This choice makes sure that most
inferred node directed links among nodes are retained.
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